BACKGROUND: Osteoporosis is a complication of multiple sclerosis (MS), especially if corticosteroid therapy is given. Little is known about the effect on bone of immunomodulatory therapy (IMT) for MS. AIM: We sought to evaluate bone mass in patients with MS on IMT. METHODS: We measured bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) in 37 patients with MS who received IMT. Different IMTs were administered: interferon beta-1a in 70%, interferon beta-1b in 27% and Glatiramer in 3%. High-dose pulse corticosteroid therapy (intravenous methylprednisolone 500 mg) was given to 81% ranging from 1 to 17 courses. RESULTS: Both mean BMD Z-score at spine of 0.53 (CI, 0.15-0.92; P = 0.0084) and mean BMD Z-score at femur of 0.72 (CI, 0.42-1.01; P < 0.0001) were significantly greater than zero. CONCLUSIONS: IMT may have a favorable effect on bone in patients with MS even in the presence of pulse steroid therapy.
BACKGROUND:Osteoporosis is a complication of multiple sclerosis (MS), especially if corticosteroid therapy is given. Little is known about the effect on bone of immunomodulatory therapy (IMT) for MS. AIM: We sought to evaluate bone mass in patients with MS on IMT. METHODS: We measured bone mineral density (BMD) by dual energy X-ray absorptiometry (DXA) in 37 patients with MS who received IMT. Different IMTs were administered: interferon beta-1a in 70%, interferon beta-1b in 27% and Glatiramer in 3%. High-dose pulse corticosteroid therapy (intravenous methylprednisolone 500 mg) was given to 81% ranging from 1 to 17 courses. RESULTS: Both mean BMD Z-score at spine of 0.53 (CI, 0.15-0.92; P = 0.0084) and mean BMD Z-score at femur of 0.72 (CI, 0.42-1.01; P < 0.0001) were significantly greater than zero. CONCLUSIONS: IMT may have a favorable effect on bone in patients with MS even in the presence of pulse steroid therapy.
Authors: Sanford Baim; Neil Binkley; John P Bilezikian; David L Kendler; Didier B Hans; E Michael Lewiecki; Stuart Silverman Journal: J Clin Densitom Date: 2008 Jan-Mar Impact factor: 2.617
Authors: A C Looker; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse; C C Johnston; R L Lindsay Journal: Osteoporos Int Date: 1995 Impact factor: 4.507
Authors: J L Pérez Castrillón; M Cano-del Pozo; S Sanz-Izquierdo; J Velayos-Jiménez; W Dib-Wobakin Journal: Rev Neurol Date: 2003 May 16-31 Impact factor: 0.870